

THIS IS A PUBLIC OFFERING OF INFORMATION FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS OR STATEMENT OF FACTS OR AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR UNITS OR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA. THE EQUITY SHARES OF OUR COMPANY WILL GET LISTED ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED.



(Please scan the QR code to view the RHP)

KRONOX

KRONOX LAB SCIENCES LIMITED

CORPORATE IDENTITY NUMBER: U24117GJ2008PLC055460

Our Company was incorporated on November 18, 2008 as 'Kronox Lab Sciences Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 18, 2008 issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our shareholders at an extra-ordinary general meeting held on May 25, 2019 and a fresh certificate of incorporation dated June 11, 2019 was issued by the Registrar of Companies, Ahmedabad consequent upon conversion, recording the change in the name of our Company to 'Kronox Lab Sciences Limited'. For further details on the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 201 of the Red Herring Prospectus (RHP).

Registered Office: Block No.353, Village Ekalbara, Padra, Vadodara 391 440, Gujarat, India; **Tel:** +91 26 6224 4077/88,

Corporate Office: Block No.284, Village Ekalbara, Padra, Vadodara 391 440, Gujarat, India; **Contact Person:** Nikhil Goswami, Company Secretary and Compliance Officer, **E-mail:** cs@kronoxlabsciences.com; **Website:** www.kronoxlabsciences.com

OUR PROMOTERS: JOGINDERSINGH JASWAL, KETAN RAMANI AND PRITESH RAMANI

INITIAL PUBLIC OFFERING OF UP TO 95,70,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF KRONOX LAB SCIENCES LIMITED ("OUR COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ [●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION ("OFFER"). THE OFFER COMPRISES AN OFFER FOR SALE OF UP TO 31,90,000 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY JOGINDERSINGH JASWAL, UP TO 31,90,000 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY KETAN RAMANI AND UP TO 31,90,000 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY PRITESH RAMANI (COLLECTIVELY, "PROMOTER SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE BY THE PROMOTER SELLING SHAREHOLDERS, "OFFER FOR SALE").

CORRIGENDUM: NOTICE TO INVESTORS

The Company has issued RHP dated May 28, 2024 ("RHP") in respect of Offer of the Company which will open for subscription on Monday, June 3, 2024 and will close on Wednesday, June 5, 2024.

Attention of investors is drawn to the following:

1. The details of selling commission under serial number 4 in section titled "Objects of the Offer – Offer Related Expenses" on page 89 of RHP:

"(2)

Portion for Retail Individual Bidders	35% of the Amount Allotted* (plus applicable taxes)
Portion for Non-Institutional Bidders	15% of the Amount Allotted* (plus applicable taxes)"

Shall now be read as:

"(2)

Portion for Retail Individual Bidders	0.35% of the Amount Allotted* (plus applicable taxes)
Portion for Non-Institutional Bidders	0.15% of the Amount Allotted* (plus applicable taxes)"

2. The details of selling commission under serial number 4 in section titled "Objects of the Offer – Offer Related Expenses" on page 90 of RHP:

"(4)

Portion for Retail Individual Bidders*	35% of the Amount Allotted* (plus applicable taxes)
Portion for Non-Institutional Bidders*	15% of the Amount Allotted* (plus applicable taxes)"

Shall now be read as:

"(4)

Portion for Retail Individual Bidders	0.35% of the Amount Allotted* (plus applicable taxes)
Portion for Non-Institutional Bidders	0.15% of the Amount Allotted* (plus applicable taxes)"

3. Under the section titled "Definitions and Abbreviations – Offer Related Terms" on page 13 of the RHP, the definition of Syndicate Agreement stating:

Syndicate Agreement	Agreement dated May 18, 2024 entered into among our Company, Promoter Selling Shareholders, the BRLM and the Syndicate Members in relation to collection of Bid cum Application Forms by the Syndicate
---------------------	--

Shall now be read as:

Syndicate Agreement	Agreement dated May 18, 2024 and Amendment to Syndicate Agreement dated May 30, 2024 entered into among our Company, Promoter Selling Shareholders, the BRLM and the Syndicate Members in relation to collection of Bid cum Application Forms by the Syndicate
---------------------	--

4. Under serial number (e) of "A. Material Contracts for the Offer" in chapter titled "Material Contracts and Documents for Inspection" on page 389 of the RHP:

"(e) Syndicate Agreement dated May 18, 2024 between our Company, Promoter Selling Shareholders, the Book Running Lead Manager and Registrar to the Offer and Syndicate Members."

Shall now be read as:

"(e) Syndicate Agreement dated May 18, 2024 and Amendment to Syndicate Agreement dated May 30, 2024 between our Company, Promoter Selling Shareholders, the Book Running Lead Manager and Registrar to the Offer and Syndicate Members."

All capitalised terms used in this Corrigendum shall, unless the context otherwise requires, have the meaning ascribed in the RHP. The RHP shall be read in conjunction with this Corrigendum. The RHP stands amended to the extent stated hereinabove. The relevant changes shall be reflected in the Prospectus when filed with the RoC, the SEBI and the Stock Exchanges.

On behalf of **Kronox Lab Sciences Limited**

Sd/-

Nikhil Goswami

Company Secretary and Compliance Officer

Place : Vadodara

Date : May 30, 2024

<p>BOOK RUNNING LEAD MANAGER</p>  <p>Pantomath Capital Advisors Private Limited Pantomath Nucleus House, Saki Vihar Road, Andheri East, Mumbai - 400072 Maharashtra, India Tel: 1800 889 8711 E-mail: kronox ipo@pantomathgroup.com Website: www.pantomathgroup.com Investor grievance e-mail: investors@pantomathgroup.com Contact Person: Kaushal Patwa SEBI Registration No.: INM000012110</p>	<p>REGISTRAR TO THE OFFER</p>  <p>KFin Technologies Limited Selenium Tower B, Plot No. 31-32, Gachibowli Financial District, Nanakramguda, Serilingampally, Hyderabad 500 032, Telangana, India Telephone: +91 40 6716 2222/ 1800 309 4001 Email: klsi.ipo@kfintech.com Investor grievance email: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: M Murali Krishna SEBI Registration No.: INR000000221</p>	<p>COMPANY SECRETARY AND COMPLIANCE OFFICER</p> <p>Nikhil Goswami KRONOX LAB SCIENCES LIMITED Block No. 353, Village Ekalbara, Padra, Vadodara 391 440, Gujarat, India Tel.: +91 26 622 44 077; E-mail: cs@kronoxlabsciences.com Website: www.kronoxlabsciences.com</p> <p>Bidders may contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-Offer or post-Offer related grievances including non-receipt of letters of Allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all Offer related queries and for redressal of complaints, investors may also write to the BRLM.</p>
---	--	--

KRONOX LAB SCIENCES LIMITED is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed a red herring prospectus dated May 28, 2024 with the RoC. The RHP is available on the websites of SEBI (www.sebi.gov.in), BRLM (www.pantomathgroup.com), NSE (www.nseindia.com), BSE (www.bseindia.com) and the Company (www.kronoxlabsciences.com). Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section titled "Risk Factors" beginning on page 31 of the RHP. Potential investors should not rely on the DRHP for making any investment decision but can only rely on the information included in the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in 'offshore transactions' in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made. There will be no public offering of Equity Shares in the United States.

CONCEPT